Ösophaguskarzinom und Karzinom des gastroösophagealen Überganges

  • J. Boda-Heggemann
  • D. Bürgy
  • U. Ronellenfitsch
  • P. Fritz
  • F. Lohr


Derzeit existiert keine nationale Leitlinie für die Diagnostik, Therapie und Nachsorge des Ösophaguskarzinoms. Das Erscheinen einer solchen Leitlinie ist für 2015 geplant (


  1. Abnet CC et al.(2009) Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100(3): 551 557Google Scholar
  2. Ajani JA et al. (2011) Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 9(8): 830–887PubMedGoogle Scholar
  3. Allum WH et al. (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27(30): 5062–5067PubMedGoogle Scholar
  4. Amenabar A., Hoppo T, Jobe BA (2013) Surgical management of gastroesophageal junction tumors. Semin Radiat Oncol, 23(1): 16–23PubMedGoogle Scholar
  5. Ancon, E et al. (2008) Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 15(11): 3278–88Google Scholar
  6. Anderson LL, Lad TE (1982) Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer 50(8): 1587–1590PubMedGoogle Scholar
  7. Arnott SJ et al. (2005) Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev (4): CD001799.PubMedGoogle Scholar
  8. Atkins BZ et al. (2004) Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg. 78(4): 1170–1176PubMedGoogle Scholar
  9. Bang YJ et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813): 315–321PubMedGoogle Scholar
  10. Bang YJ et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376(9742):687–697PubMedGoogle Scholar
  11. Barzi A, Lenz HJ (2012) Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 12(10): 1335–1345PubMedGoogle Scholar
  12. Baumhoer D, Ramadori G (2005) Ösophaguskarzinome - aktueller Stand der Diagnostik und Therapie. Z Gastroenterol 43(4): 399–409PubMedGoogle Scholar
  13. Beatty JD, DeBoer G,. Rider WD (1979) Carcinoma of the esophagus: pretreatment assessment, correlation of radiation treatment parameters with survival, and identification and management of radiation treatment failure. Cancer. 43(6): 2254–2267PubMedGoogle Scholar
  14. Bedard ELet al. (2001) The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 91(12): 2423–2430PubMedGoogle Scholar
  15. Bedenne, L et al. (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 25(10): 1160–1168PubMedGoogle Scholar
  16. Bennett C et al. (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 143(2): 336–346PubMedGoogle Scholar
  17. Biere SS et al. (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 379(9829):1887–1892PubMedGoogle Scholar
  18. Birkmeyer JD et al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med. 346(15): 1128–1137PubMedGoogle Scholar
  19. Birkmeyer JD et al. (2003) Surgeon volume and operative mortality in the United States. N Engl J Med. 349(22): 2117–2127PubMedGoogle Scholar
  20. Bleiberg H et al. (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 33(8): 1216–1220PubMedGoogle Scholar
  21. Bollschweiler E, Holscher AH (2007) Prognosis of early esophageal cancer: differences between squamous cell carcinoma and adenocarcinoma. Ann Surg. 245(2): 334PubMedGoogle Scholar
  22. Borchard, F (1985) Epidemiologie, Ätiologie und pathologische Anatomie des Ösophaguskarzinoms. in: Denck H, Paquet KJ, Zöckler CE (Hrsg.). Chirurgische Gastroenterologie mit interdisziplinären Gesprächen, TM Verlag, Hameln. Nr. 2(8/85): 7–15Google Scholar
  23. Bosset, JF et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 337(3): 161–167PubMedGoogle Scholar
  24. Brown, LM, Devesa SS, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 100(16): 1184–1187PubMedGoogle Scholar
  25. Buas MF, Vaughan TL (2013) Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 23(1): 3–9PubMedGoogle Scholar
  26. Buergy, D et al. (2012) Radiotherapy for tumors of the stomach and gastroesophageal junction–a review of its role in multimodal therapy. Radiat Oncol. 7: 192PubMedGoogle Scholar
  27. Burmeister, BH et al. (2011) A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 6(12): p. 2076–2082PubMedGoogle Scholar
  28. zum Buschenfelde CM et al. (2011) (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 52(8): 1189–1196Google Scholar
  29. Bystricky B, Okines AF, Cunningham D (2011) Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 71(5): p. 541–555PubMedGoogle Scholar
  30. Caspers RJ et al. (1993) Combined external beam and low dose rate intraluminal radiotherapy in oesophageal cancer. Radiother Oncol. 27(1): 7–12PubMedGoogle Scholar
  31. Chakravarty T et al. (2010) Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 83(2): 581–586Google Scholar
  32. Conroy T et al. (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol. 14(1): 164–170PubMedGoogle Scholar
  33. Cooper JS et al. (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281(17): 1623–1627PubMedGoogle Scholar
  34. Cooper SC et al. (2010) The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev, 2010. 19(3): p. 182–185PubMedGoogle Scholar
  35. Corley A, Kubo A, Zhao W (2008) Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 17(2): 352–358PubMedGoogle Scholar
  36. Cunningham D et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006. 355(1): 11–20PubMedGoogle Scholar
  37. Cunningham E (2006) What is the registered dietitian’s role in the preoperative assessment of a client contemplating bariatric surgery? J Am Diet Assoc, 2006. 106(1): 163PubMedGoogle Scholar
  38. Dantoc M, Cox MR, Eslick GD (2012) Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 147(8): 768–776PubMedGoogle Scholar
  39. Das A et al. (2006) Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol. 40(5): 405–411PubMedGoogle Scholar
  40. Das D, Chilton AP, Jankowski JA, (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 181: 161–169PubMedGoogle Scholar
  41. Dikken JL et al. (2013) Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg. 100(1): 83–94PubMedGoogle Scholar
  42. Dikken JL et al. (2012) Influence of hospital type on outcomes after oesophageal and gastric cancer surgery. Br J Surg. 99(7): 954–963PubMedGoogle Scholar
  43. Dikke JL et al. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 11: 32.Google Scholar
  44. Djarv T, Lagergren P (2012) Quality of life after esophagectomy for cancer. Expert Rev Gastroenterol Hepatol. 6(1): 15–22Google Scholar
  45. Emami B et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21(1):109–122PubMedGoogle Scholar
  46. Engel LS et al. (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 95(18): 1404–1413PubMedGoogle Scholar
  47. Erickson LA (2005) Sternberg’s Diagnostic Surgical Pathology, 4th ed. The American Journal of Surgical Pathology. 29(3): 425Google Scholar
  48. Fakhrian K et al. (2013) Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma. Strahlenther Onkol. 189(4): p. 293–300PubMedGoogle Scholar
  49. Fiorica F et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut, 53(7): p. 925–930PubMedGoogle Scholar
  50. Flamen P et al. (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol, 2000. 18(18): 3202–1320PubMedGoogle Scholar
  51. Freedman ND et al. (2007) A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 165(12):1424–1433PubMedGoogle Scholar
  52. Freedman ND et al. (2011) Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 60(8): 1029–1037PubMedGoogle Scholar
  53. Fritz P, Wannenmacher M (1997) Radiotherapy in the multimodal treatment of esophageal carcinoma. A review. Strahlenther Onkol. 173(6): 295–308PubMedGoogle Scholar
  54. Fritz P et al. (2003) Concurrent chemotherapy and radiation therapy for unresectable locally advanced carcinoma of the esophagus. Phase II study and clinical review on literature. Strahlenther Onkol. 179(5): 328–36PubMedGoogle Scholar
  55. Fujiwara Y et al. (2012) Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep. 28(2): 446–452PubMedGoogle Scholar
  56. Gebski V et al. (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 2007. 8(3): 226–234PubMedGoogle Scholar
  57. de Geus-Oei, LF et al. (2012) FDG-PET/CT based response-adapted treatment. Cancer Imaging. 12(2): 324–335PubMedGoogle Scholar
  58. Gignoux M et al. (1987) The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg. 11(4): 426–432PubMedGoogle Scholar
  59. Greenwald BD et al. (2010) Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc. 71(4): 686–693PubMedGoogle Scholar
  60. van Hagen P et al. (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366(22): 2074–2084PubMedGoogle Scholar
  61. Haneder S et al. (2012) Assessment of renal function after conformal radiotherapy and intensity modulated radiotherapy by functional 1H-MR-imaging and 23Na-MR-imaging. Strahlenther Onkol Dec; 188 (12): 1146–1154Google Scholar
  62. Hardikar S et al. (2013) The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS One. 8(1): p. e52192PubMedGoogle Scholar
  63. Hasegawa S et al. (2013) Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol. 20(3): 773–779PubMedGoogle Scholar
  64. Herskovic A et al. (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 1992. 326(24): 1593–1598PubMedGoogle Scholar
  65. Holscher, A.H et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg. 254(5): p. 802–7; discussion 807–8.Google Scholar
  66. Homs MY (2004) et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 364(9444): 1497–1504PubMedGoogle Scholar
  67. Hsu FM et al. (2011) Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 81(4): e593–599PubMedGoogle Scholar
  68. Huber K. (2013) Karzinom des Ösophagus und des gastroösophagealen Übergangs. Strahlentherapie und Onkologie February, Volume 189, ”/journal/66/189/2/page/Issue 2: 161–162Google Scholar
  69. Hulscher JB et al. (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 347(21): 1662–1669PubMedGoogle Scholar
  70. Idelevich E et al. (2012) Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie. 35(7–8): 427–431PubMedGoogle Scholar
  71. Ilson DH et al. (2007) Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 18(5): 898–902PubMedGoogle Scholar
  72. Ilson,DH et al. (2012) Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 118(11): 2820–2822Google Scholar
  73. Isolauri J, Markkula H, (1989) Lye ingestion and carcinoma of the esophagus. Acta Chir Scand. 155(4–5): p. 269–71.PubMedGoogle Scholar
  74. Jackson A et al. (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 76(3 Suppl): 155–160Google Scholar
  75. Jemal A et al. (2011) Global cancer statistics. CA Cancer J Clin. 61(2): 69–90PubMedGoogle Scholar
  76. Kamangar F et al. (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 98(20): 1445–1452PubMedGoogle Scholar
  77. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24(14): 2137–2150PubMedGoogle Scholar
  78. Kato K et al. (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 81(3): 684–690PubMedGoogle Scholar
  79. Kelsen DP et al. (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25(24): 3719–3725PubMedGoogle Scholar
  80. Klautke G, Fietkau R, Significance of radiation therapy for adenocarcinomas of the esophagus, gastroesophageal junction and gastric cancer with special reference to the MAGIC trial. Strahlenther Onkol. 183(4): 163–169Google Scholar
  81. Kleinberg L (2013) Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: optimizing outcome. Semin Radiat Oncol. 23(1): 38–50PubMedGoogle Scholar
  82. Kmet J, Mahboubi E (1972) Esophageal cancer in the Caspian littoral of Iran: initial studies. Science. 175(4024): 846–853PubMedGoogle Scholar
  83. Kole TP et al. (2012) Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 83(5): 1580–1586PubMedGoogle Scholar
  84. Kranzfelder M et al. (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 98(6): 768–783PubMedGoogle Scholar
  85. Ku GY, Ilson DH (2012) Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointest Cancer Res. 5(3): 85–92PubMedGoogle Scholar
  86. Launois B et al. (1981) Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet. 153(5): 690–692PubMedGoogle Scholar
  87. Lee, J et al. (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 30(3): 268–723PubMedGoogle Scholar
  88. Liao LM et al. (2012) Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology, 2012. 142(3): p. 442–452 e5; quiz e22–3PubMedGoogle Scholar
  89. Lightdale CJ (1995) Photodynamic therapy: a new light on Barrett’s esophagus. Gastrointest Endosc. 42(1): 96–98PubMedGoogle Scholar
  90. Lin SH et al. (2012) Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. Int J Radiat Oncol Biol PhysGoogle Scholar
  91. Lin SH et al. (2012) Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 83(3): e345–351PubMedGoogle Scholar
  92. Lordick F et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8(9): 797–805PubMedGoogle Scholar
  93. Lorenzen S et al. (2011) Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 11: 266PubMedGoogle Scholar
  94. Lowe WC (1972) Survival with carcinoma of the esophagus. Ann Intern Med. 77(6): 915–918PubMedGoogle Scholar
  95. Lutz MP et al. (2012) Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 48(16): 2941–2953PubMedGoogle Scholar
  96. Macdonald JS et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345(10): 725–730PubMedGoogle Scholar
  97. Malthaner R, Wong RK, Spithoff K (2010) Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 22(4): 250–256Google Scholar
  98. Marger RS, D. Marger D (1993) Carcinoma of the esophagus and tylosis. A lethal genetic combination. Cancer. 72(1): p.17–19PubMedGoogle Scholar
  99. Mariette C, Piessen G (2012) Oesophageal cancer: how radical should surgery be? Eur J Surg Oncol. 38(3): 210–213PubMedGoogle Scholar
  100. Matuschek C et al. (2011) Trimodal therapy in squamous cell carcinoma of the esophagus. Eur J Med Res. 16(10): 437–444PubMedGoogle Scholar
  101. Matzinger O et al. (2009) EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 92(2): 164–175PubMedGoogle Scholar
  102. Minsky BD et al. (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20(5): 1167–1174PubMedGoogle Scholar
  103. Nishihira T, Hirayama, K, Mori S, (1998) A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 175(1): 47–51PubMedGoogle Scholar
  104. Nomura M et al. (2012) Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 82(2): 946–952PubMedGoogle Scholar
  105. Nygaard K et al. (1992) Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 16(6): p. 1104–1109; discussion 1110PubMedGoogle Scholar
  106. Offner FA (2000) Ätiologie, Molekularbiologie und Pathologie des Plattenepithelkarzinoms des Ösophagus. Der Pathologe. 21(5): 349–357PubMedGoogle Scholar
  107. Oh DS, Demeester SR (2010) Pathophysiology and treatment of Barrett’s esophagus. World J Gastroenterol. 16(30): 3762–3772Google Scholar
  108. Ojala K et al. (1982) Symptoms of carcinoma of the oesophagus. Med J Aust. 1(9): 384–385PubMedGoogle Scholar
  109. Orlando RC (2005) Pathogenesis of reflux esophagitis and Barrett’s esophagus. Med Clin North Am. 89(2): 219–241PubMedGoogle Scholar
  110. Overholt BF et al. (2007) Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 66(3): p. 460–468PubMedGoogle Scholar
  111. Pasini F et al. (2012) Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer. 119(5): 939–945PubMedGoogle Scholar
  112. Pennathur A et al. (2013) Oesophageal carcinoma. Lancet. 381(9864): 400–412PubMedGoogle Scholar
  113. Perez CA., Brady LW, Halperin EC, (Hrsg) (2008) Perez and Brady’s principles and practice of radiation oncology : [now in color throughout and including fully searchable online text and image bank]. 5. ed. ed. Wolters Kluwer Health. Wolters Kluwer, Lippincott Williams & Wilkins: Philadelphia, Pa. [u.a.].Google Scholar
  114. Pohl H et al. (2013) Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 108(2): 200–207PubMedGoogle Scholar
  115. Power DG, Ilson DH (2009) Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol. 1(3): 145–165PubMedGoogle Scholar
  116. Qumseya BJ, David W, Wolfsen HC (2013) Photodynamic Therapy for Barrett’s Esophagus and Esophageal Carcinoma. Clin Endosc. 46(1): 0–7Google Scholar
  117. Rawat S et al. (2013) Chemoradiotherapy in the Management of Locally Advanced Squamous Cell Carcinoma Esophagus: Is Surgical Resection Required? J Gastrointest Cancer.Google Scholar
  118. Rice TW, Blackstone EH, and Rusch VW (2010) 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 17(7): p. 1721–1724PubMedGoogle Scholar
  119. Rice TW et al. (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 116(16): 3763–3773PubMedGoogle Scholar
  120. Richards et al. (2013) Results of docetaxel plus oxaliplatin (DOCOX) ±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study. European Journal of Cancer in pressGoogle Scholar
  121. Robertson R, Coy P, Mokkhavesa S (1967) The results of radical surgery compared with radical radiotherapy in the treatment of squamous carcinoma of the thoracic esophagus. The case for preoperative radiotherapy. J Thorac Cardiovasc Surg. 53(3): 430–440PubMedGoogle Scholar
  122. Ruhstaller T et al. (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol. 29(6): 626–631PubMedGoogle Scholar
  123. Sack H, Thesen N (1998) Bestrahlungsplanung, 2. Aufl., Thieme, Stuttgart New York.Google Scholar
  124. Sadeghi S et al. (2008) Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 17(5): 1169–1178Google Scholar
  125. Sahgal A et al. (2012) Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 82(1): 107–116PubMedGoogle Scholar
  126. Sakuramoto S et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357(18): 1810–1820PubMedGoogle Scholar
  127. Sandler RS et al. (1995) The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. 274(17): 1359–1362PubMedGoogle Scholar
  128. Schieman C et al. (2013) Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy. Ann Thorac Surg. 95(2): p. 459–463PubMedGoogle Scholar
  129. Shaheen NJ, Spechler SJ (2008) Total endoscopic eradication of Barrett’s esophagus: study methodology, candidate selection, and clinical outcomes. Endoscopy. 40(12): 994–999PubMedGoogle Scholar
  130. Sharma P (2009) Clinical practice. Barrett’s esophagus. N Engl J Med. 361(26): 2548–2556PubMedGoogle Scholar
  131. Shridhar R et al. (2013) Radiation therapy and esophageal cancer. Cancer Control. 20(2): 97–110PubMedGoogle Scholar
  132. Siewert JR et al. (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 234(3): 360–367; discussion 368–369PubMedGoogle Scholar
  133. Siewert JR et al. (1987) Kardiakarzinom: Versuch einer therapeutisch relevanten Klassifikation. Chirurg. 58(1): 25–32PubMedGoogle Scholar
  134. Siewert JR, Stein HJ, Feith M (2006) Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 95(4): 260–269Google Scholar
  135. Sjoquist KM et al. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12(7): 681–692Google Scholar
  136. Smit JK et al. (2013) Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. Ann Surg Oncol.Jun; 20(6): 1985–1992Google Scholar
  137. Stahl M et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 23(10): 2310–2317Google Scholar
  138. Stahl M et al. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 27(6): 851–856Google Scholar
  139. Sterzing F, Grenacher L, Debus J (2012) Radiotherapy of gastroesophageal junction cancer. Recent Results Cancer Res. 196: 187–99Google Scholar
  140. Stieler F et al. (2011) A comparison of several modulated radiotherapy techniques for head and neck cancer and dosimetric validation of VMAT. Radiother Oncol. 101(3): 388–393Google Scholar
  141. Suh YS et al. (2012) Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 255(5): 908–915Google Scholar
  142. Suzuki A et al. (2011) Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 117(21): 4823–4833Google Scholar
  143. Saarländisches Krebsregister 2012.Google Scholar
  144. Teniere P et al. (1991) Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 173(2): 123–130Google Scholar
  145. Thrift AP et al. (2013) A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 11(2): p. 138–44 e2Google Scholar
  146. Urba SG et al. (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19(2): 305–313Google Scholar
  147. Urschel JD, Vasan (2003), A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 185(6): 538–543Google Scholar
  148. Vakil N et al. (2001) A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol. 96(6): p. 1791–1796Google Scholar
  149. Vaughan.L et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 6(12): 945–952Google Scholar
  150. Vaughan TL, Kiemeney LA, McKnight B (1995) Colorectal cancer in patients with esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 4(2): 93–97Google Scholar
  151. Walsh TN et al. (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335(7): 462–467Google Scholar
  152. Wang, DB et al. (2012) Neoadjuvant Chemoradiotherapy Could Improve Survival Outcomes for Esophageal Carcinoma: A Meta-Analysis. Dig Dis Sci.Google Scholar
  153. Wara WM et al. (1976) Palliation for carcinoma of the esophagus. Radiology. 121(3 Pt. 1): 717–720Google Scholar
  154. Weber WA et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 19(12): 3058–3065Google Scholar
  155. Welsh J et al. (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 81(5): 1336–1342Google Scholar
  156. van Westreenen HL et al. (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 22(18): 3805–3812Google Scholar
  157. Whiteman DC et al. (2010) Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology. 139(1): 73–83; quiz e11–2Google Scholar
  158. Wittekind C (Hrsg) (2010) TNM-Klassifikation maligner Tumoren. 7. Aufl. Wiley-Blackwell: Weinheim. XIX, 295Google Scholar
  159. Wong RK et al. (2003) Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 55(4): 930–942Google Scholar
  160. Wu AJ, Goodman KA (2013) Positron emission tomography imaging for gastroesophageal junction tumors. Semin Radiat Oncol. 23(1): 10–15Google Scholar
  161. Yamamoto M et al. (1997) Reevaluation of postoperative radiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 37(1): 75–78Google Scholar
  162. Huber K (2013) Überleben durch neoadjuvante Radiochemotherapie verbessert Strahlenther Onkol. 189(2): 161–162Google Scholar
  163. Ychou M et al. (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29(13): 1715–1721Google Scholar
  164. Yoo C et al. (2012) Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg. 94(6): 1862–1868Google Scholar
  165. Yoon HH et al. (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 30(32): 3932–3938Google Scholar
  166. Yu C et al. (2012) Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol. 138(2): 255–259Google Scholar
  167. Zhu WG et al. (2012) A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol.Google Scholar
  168. Zieren HU et al. (1995) Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 19(3): 444–449Google Scholar
  169. Zimmermann JS, Kumpf L, Kimmig B (1998) Variability of individual normal tissue radiation sensitivity. An international empirical evaluation of endogenous and exogenous response modifiers. Strahlenther Onkol. 174 Suppl 3: 16–19Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • J. Boda-Heggemann
    • 1
  • D. Bürgy
    • 2
  • U. Ronellenfitsch
    • 3
  • P. Fritz
    • 4
  • F. Lohr
    • 5
  1. 1.Klinik für Strahlentherapie und RadioonkologieUniversitätsmedizin Mannheim, Universität HeidelbergMannheimDeutschland
  2. 2.Klinik für Strahlentherapie und RadioonkologieUniversitätsklinikum MannheimMannheimDeutschland
  3. 3.chirurgische KlinikUniversitätsmedizin MannheimMannheimDeutschland
  4. 4.Klinik für Radio-OnkologieSt. MarienkrankenhausSiegenDeutschland
  5. 5.Klinik für Strahlentherapie und RadioonkologieMannheimDeutschland

Personalised recommendations